Prolactin increases SMN expression and survival in a mouse model of severe spinal muscular atrophy via the STAT5 pathway.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Clinical Investigation

• Publication date

  2011-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1172/JCI46276PMID 21785216PMCID PMC3148738
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN

  2011cited by this paper
• Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice.

  2011cited by this paper
• Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model.

  2010cited by this paper
• Recombinant human prolactin for the treatment of lactation insufficiency

  2010cited by this paper
• Genetic therapy for spinal muscular atrophy

  2010cited by this paper
• Systemic Delivery of scAAV9 Expressing SMN Prolongs Survival in a Model of Spinal Muscular Atrophy

  2010cited by this paper
• Cardiac defects contribute to the pathology of spinal muscular atrophy models.

  2010cited by this paper
• Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN

  2010cited by this paper
• Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model.

  2010cited by this paper
• CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy.

  2010cited by this paper
• Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery.

  2010cited by this paper
• SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy.

  2010cited by this paper
• Digital necroses and vascular thrombosis in severe spinal muscular atrophy

  2010cited by this paper
• Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice.

  2010cited by this paper
• Oligonucleotide-Mediated Survival of Motor Neuron Protein Expression in CNS Improves Phenotype in a Mouse Model of Spinal Muscular Atrophy

  2009cited by this paper
• Vascular perfusion abnormalities in infants with spinal muscular atrophy.

  2009cited by this paper
• The neuroprotective factor Wld(s) fails to mitigate distal axonal and neuromuscular junction (NMJ) defects in mouse models of spinal muscular atrophy.

  2009cited by this paper
• p38 Mitogen-activated protein kinase stabilizes SMN mRNA through RNA binding protein HuR.

  2009cited by this paper
• [Prolactinomas: diagnosis and treatment].

  2009cited by this paper
• Pathogenesis of proximal autosomal recessive spinal muscular atrophy

  2008cited by this paper
• Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice

  2008cited by this paper
• Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle-specific SMN expression has no phenotypic effect.

  2008cited by this paper
• White Matter Plasticity and Enhanced Remyelination in the Maternal CNS

  2007cited by this paper
• Stat5 constitutive activation rescues defects in spinal muscular atrophy.

  2007influential reference
• STAT5A/B activity is required in the developing forebrain and spinal cord.

  2007cited by this paper
• Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy.

  2007cited by this paper
• Spinal muscular atrophy and therapeutic prospects.

  2006cited by this paper
• SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN.

  2005influential reference
• Coupled in vitro import of U snRNPs and SMN, the spinal muscular atrophy protein.

  2004cited by this paper
• Direct Interaction of the Spinal Muscular Atrophy Disease Protein SMN with the Small Nucleolar RNA-associated Protein Fibrillarin*

  2001cited by this paper
• The survival of motor neurons (SMN) protein interacts with the snoRNP proteins fibrillarin and GAR1.

  2001cited by this paper
• A Functional Interaction between the Survival Motor Neuron Complex and RNA Polymerase II

  2001cited by this paper
• SMN interacts with a novel family of hnRNP and spliceosomal proteins

  2001cited by this paper
• Characterization of a nuclear 20S complex containing the survival of motor neurons (SMN) protein and a specific subset of spliceosomal Sm proteins.

  2000cited by this paper
• Specific Sequences of the Sm and Sm-like (Lsm) Proteins Mediate Their Interaction with the Spinal Muscular Atrophy Disease Gene Product (SMN)*

  2000cited by this paper
• Prolactin (PRL)-PRL receptor system increases cell proliferation involving JNK (c-Jun amino terminal kinase) and AP-1 activation: inhibition by glucocorticoids.

  2000cited by this paper
• A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy.

  1999cited by this paper
• From the molecular biology of prolactin and its receptor to the lessons learned from knockout mice models.

  1999cited by this paper
• SMN mutants of spinal muscular atrophy patients are defective in binding to snRNP proteins.

  1999cited by this paper
• Essential role for the tudor domain of SMN in spliceosomal U snRNP assembly: implications for spinal muscular atrophy.

  1999cited by this paper
• A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2.

  1999cited by this paper
• Activation of the Jak2-Stat5 Signaling Pathway in Nb2 Lymphoma Cells by an Anti-apoptotic Agent, Aurintricarboxylic Acid*

  1998influential reference
• Genomic variation and gene conversion in spinal muscular atrophy: implications for disease process and clinical phenotype.

  1997cited by this paper
• Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos.

  1997cited by this paper
• The SMN-SIP1 complex has an essential role in spliceosomal snRNP biogenesis.

  1997cited by this paper
• Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number.

  1997cited by this paper
• The prolactin receptor in the fetal rat: cellular localization of messenger ribonucleic acid, immunoreactive protein, and ligand-binding activity and induction of expression in late gestation.

  1995cited by this paper
• Identification and characterization of a spinal muscular atrophy-determining gene

  1995influential reference
• Population frequencies of inherited neuromuscular diseases--a world survey.

  1991cited by this paper
• Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q1 1.2–13.3

  1990cited by this paper
• Gene for chronic proximal spinal muscular atrophies maps to chromosome 5q

  1990cited by this paper
• Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3.

  1990cited by this paper
• Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy.

  1978cited by this paper

• [Research progress on phenotypic modifier genes in spinal muscular atrophy].

  2025cites this paper
• Oligodendrocyte-Specific STAT5B Overexpression Ameliorates Myelin Impairment in Experimental Models of Parkinson’s Disease

  2025cites this paper
• Elevated Prolactin Levels Are Associated With Increased Severity and Psychiatric Symptoms in Anti‐N‐Methyl‐D‐Aspartate Receptor Encephalitis

  2025cites this paper
• Identification of key genes and signaling pathways based on transcriptomic studies of aerobic and resistance training interventions in sarcopenia in SAMP8 mice

  2024cites this paper
• Nonalcoholic Fatty Liver Disease, Bone and Muscle Quality in Prolactinoma: A Pilot Study.

  2024cites this paper
• MiR34 contributes to spinal muscular atrophy and AAV9-mediated delivery of MiR34a ameliorates the motor deficits in SMA mice.

  2023cites this paper
• Recombinant Mouse Prolactin Confers Partial Protection Against Toxoplasma gondii Infection in a Pre-treated Experimental Murine Model

  2022cites this paper
• Spinal muscular atrophy

  2022cites this paper
• Spinal muscular atrophy: Broad disease spectrum and sex-specific phenotypes.

  2021cites this paper
• The role of prolactin in central nervous system inflammation

  2021cites this paper
• A high-throughput genome-wide RNAi screen identifies modifiers of survival motor neuron protein

  2021cites this paper
• Decoding signaling pathways involved in prolactin-induced neuroprotection: a review.

  2021cites this paper
• Repurposing Domperidone in Secondary Progressive Multiple Sclerosis

  2021cites this paper
• The Importance of Digging into the Genetics of SMN Genes in the Therapeutic Scenario of Spinal Muscular Atrophy

  2021cites this paper
• Prolactin and Its Altered Action in Alzheimer’s Disease and Parkinson’s Disease

  2021cites this paper
• The First Orally Deliverable Small Molecule for the Treatment of Spinal Muscular Atrophy

  2020cites this paper
• Domperidone-induced elevation of serum prolactin levels and immune response in multiple sclerosis.

  2019cites this paper
• Neuroprotection in Neurodegenerative Disorders

  2019cites this paper
• Spinal muscular atrophy – a revisit of the diagnosis and treatment modalities

  2019cites this paper
• Pharmacological c-Jun NH2-Terminal Kinase (JNK) Pathway Inhibition Reduces Severity of Spinal Muscular Atrophy Disease in Mice

  2018cites this paper
• Molecular Factors Involved in Spinal Muscular Atrophy Pathways as Possible Disease-modifying Candidates

  2018influential citation
• Light modulation ameliorates expression of circadian genes and disease progression in spinal muscular atrophy mice

  2018cites this paper
• Insights into the pharmaceuticals and mechanisms of neurological orphan diseases: Current Status and future expectations

  2018cites this paper
• Advances in therapy for spinal muscular atrophy: promises and challenges

  2018cites this paper
• Impact of sex hormones on immune function and multiple sclerosis development

  2018cites this paper
• Repurposing Clinic-Tested Drugs to Treat Rare Neurogenetic Diseases by Transcriptional Modulation

  2018cites this paper
• NGS Technologies as a Turning Point in Rare Disease Research, Diagnosis and Treatment

  2017cites this paper
• An Introduction to the Natural History, Genetic Mapping, and Clinical Spectrum of Spinal Muscular Atrophy

  2017cites this paper
• Small Molecule Approaches to Upregulate SMN Expression From the SMN2 Locus

  2017cites this paper
• Spinal Muscular Atrophy Therapeutics Development

  2017cites this paper
• Chapter 5 – Transcriptional and Splicing Regulation of Spinal Muscular Atrophy Genes

  2017cites this paper
• Spinal Muscular Atrophy Disease Modifiers

  2017cites this paper
• Molecular Mechanisms of Neurodegeneration in Spinal Muscular Atrophy

  2016cites this paper
• Targeting the ubiquitin proteasome system to develop novel therapeutic approaches for spinal muscular atrophy

  2016influential citation
• An Integrative Transcriptomic Analysis for Identifying Novel Target Genes Corresponding to Severity Spectrum in Spinal Muscular Atrophy

  2016cites this paper
• Advances and challenges in developing a therapy for spinal muscular atrophy

  2015cites this paper
• Spinal muscular atrophies.

  2015cites this paper
• Genetic inhibition of JNK3 ameliorates spinal muscular atrophy.

  2015cites this paper
• Prolactin: a versatile regulator of inflammation and autoimmune pathology.

  2015cites this paper
• Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.

  2015cites this paper
• Chapter 8 – Spinal Muscular Atrophies

  2015cites this paper
• Spinal muscular atrophy: review of a child onset disease.

  2015cites this paper
• Genetic inhibition of JNK 3 ameliorates spinal muscular atrophy

  2015cites this paper
• Spinal Muscular Atrophy: review of a child

  2015cites this paper
• Spinal Muscular Atrophy: review of a child

  2015cites this paper
• Spinal Muscular Atrophy: review of a child

  2015cites this paper
• Spinal muscular atrophy: a motor neuron disorder or a multi‐organ disease?

  2014cites this paper
• VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse models

  2014cites this paper
• Defining the anti-apoptotic function of the survival of motor neuron (SMN) protein and assessment of a novel therapy for the treatment of spinal muscular atrophy (SMA)

  2014cites this paper
• [Multiplex ligation-dependent probe amplification detection of spinal muscular atrophy type I in a 3 months' patient and wide detection of healthy carriers in the family].

  2014cites this paper
• Mechanisms of disease pathogenesis in Spinal Muscular Atrophy

  2014influential citation
• Human Growth Hormone Increases SMN Expression and Survival in Severe Spinal Muscular Atrophy Mouse Model

  2014influential citation
• Translational Fidelity of Intrathecal Delivery of Self-Complementary AAV9–Survival Motor Neuron 1 for Spinal Muscular Atrophy

  2014cites this paper
• Motor Neuron-Specific Restoration of SMN in Two SMA Mouse Models: Insights into the Role of Motor Neurons in Spinal Muscular Atrophy

  2014influential citation
• Advances in therapeutic development for spinal muscular atrophy.

  2014cites this paper
• Rare-disease genetics in the era of next-generation sequencing: discovery to translation

  2013cites this paper
• Spinal muscular atrophy at the crossroads of basic science and therapy.

  2013cites this paper
• Spinal muscular atrophy: an update on therapeutic progress.

  2013cites this paper
• Spinal muscular atrophy: Development and implementation of potential treatments

  2013cites this paper
• At the "junction" of spinal muscular atrophy pathogenesis: the role of neuromuscular junction dysfunction in SMA disease progression.

  2013cites this paper
• Spinal Muscular Atrophy: From Gene Discovery to Clinical Trials

  2013influential citation
• SMA-MAP: A Plasma Protein Panel for Spinal Muscular Atrophy

  2013cites this paper
• Spinal Muscular Atrophy: Classification, Diagnosis, Background, Molecular Mechanism and Development of Therapeutics

  2013cites this paper
• Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds

  2013cites this paper
• Celecoxib increases SMN and survival in a severe spinal muscular atrophy mouse model via p38 pathway activation.

  2013cites this paper
• Sodium vanadate combined with l-ascorbic acid delays disease progression, enhances motor performance, and ameliorates muscle atrophy and weakness in mice with spinal muscular atrophy

  2013cites this paper
• Spinal Muscular Atrophy and the Antiapoptotic Role of Survival of Motor Neuron (SMN) Protein

  2013cites this paper
• Current advances in drug development in spinal muscular atrophy

  2013cites this paper
• The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models.

  2013cites this paper
• Defining the therapeutic window in spinal muscular atrophy

  2013cites this paper
• Functional consequences of prolactin signalling in endothelial cells: a potential link with angiogenesis in pathophysiology?

  2012cites this paper
• New Therapeutic Approaches to Spinal Muscular Atrophy

  2012cites this paper
• Role of p38 and STAT5 Kinase pathways in the regulation of Survival of Motor Neuron gene expression for development of novel Spinal Muscular Atrophy therapeutics

  2012cites this paper
• Bzw2 Promotes Proliferation and Lactation of Mammary Epithelial Cell in Dairy Goat

  2012cites this paper
• Therapeutic strategies for the treatment of spinal muscular atrophy.

  2012cites this paper
• Co-regulation of survival of motor neuron and Bcl-xL expression: implications for neuroprotection in spinal muscular atrophy.

  2012cites this paper
• SMN-inducing compounds for the treatment of spinal muscular atrophy.

  2012cites this paper
• A generalizable pre-clinical research approach for orphan disease therapy

  2012cites this paper
• A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse.

  2012cites this paper
• Progress and promise: the current status of spinal muscular atrophy therapeutics.

  2011cites this paper
• For Spinal Muscular Atrophy Prolactin and Early Gene Restoration Show Promise

  2011cites this paper
• Of SMN in mice and men: a therapeutic opportunity.

  2011cites this paper
• International Journal of Molecular Sciences Prolactin: Friend or Foe in Central Nervous System Autoimmune Inflammation?

  year unknowncites this paper
• Degenerative Neurological and Neuromuscular Disease Dovepress Current and Emerging Treatment Options for Spinal Muscular Atrophy

  year unknowncites this paper